About
Elemental reducing agents
Areas of Focus
Categories
Small Molecule PharmaceuticalSeattle/Pacific Northwest
Clinical Trials (3)
View allTotal Trials
3
As Lead Sponsor
3
As Collaborator
0
Total Enrollment
2,479
By Phase
PHASE3: 1PHASE2: 2
By Status
COMPLETED: 2TERMINATED: 1
Clinical Trials Pipeline3 trials
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Phase 1/2
Phase 2/3
N/A
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
Today
Hover over trial bars to see details
Recent Trials
NCT04837001Lead Sponsor
Evaluation in STEMI Patients Using FDY-5301
PHASE3Completed
2,351 participants
Started: May 2, 2022 · Completed: Sep 3, 2025
NCT04430283Lead Sponsor
Evaluation of FDY-5301 in Major Trauma Patients in ICU
PHASE2Terminated
8 participants
Started: Sep 20, 2021 · Completed: Mar 4, 2022
NCT03470441Lead Sponsor
A Study of Acute Myocardial Infarction Using FDY-5301
PHASE2Completed
120 participants
Started: Oct 27, 2017 · Completed: Jan 3, 2019
Locations (1)
Headquarters
Seattle, WA, United States
Map
Loading map...